复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

交易中 01-05 10:44:10

63.500

+4.900

+8.36%

最高63.600	最低57.700	成交量41.74万
今开58.550	昨收58.600	日振幅10.07%
总市值345.12亿	流通市值103.78亿	总股本5.43亿
成交额2,560万	换手率0.26%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":63.5,"timestamp":1767581034443,"preClose":58.6,"halted":0,"volume":417400,"delay":0,"floatShares":163428541,"shares":543494853,"eps":1.6857548015893418,"marketStatus":"交易中","change":4.9,"latestTime":"01-05 10:44:10","open":58.55,"high":63.6,"low":57.7,"amount":25595188,"amplitude":0.100683,"askPrice":63.5,"askSize":800,"bidPrice":63.45,"bidSize":2200,"shortable":3,"etf":0,"ttmEps":1.6936162034825286,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1767585600000},"marketStatusCode":2,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":58.6,"openAndCloseTimeList":[[1767576600000,1767585600000],[1767589200000,1767600000000]],"volumeRatio":2.423872,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2600040688","title":"复宏汉霖注射用HLX43启动Ib/II期临床 适应症为晚期或转移性结直肠癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2600040688","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600040688?lang=zh_cn&edition=full","pubTime":"2026-01-04 18:03","pubTimestamp":1767520980,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，上海复宏汉霖生物技术股份有限公司/上海复宏汉霖生物医药有限公司的一项评估HLX43联合HLX07或斯鲁利单抗在晚期或转移性结直肠癌患者中的安全性、耐受性和有效性的Ib/II期临床研究已启动。本次试验目的为评估不同剂量水平HLX43联合HLX07或斯鲁利单抗在晚期或转移性结直肠癌患者中的安全性、耐受性和有效性。注射用HLX43为生物制品，适应症为晚期或转移性结直肠癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104190435a49ab0c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104190435a49ab0c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2600040683","title":"新药周观点：2025年约101款创新药国内获批上市 行业蓬勃发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2600040683","media":"国投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600040683?lang=zh_cn&edition=full","pubTime":"2026-01-04 00:00","pubTimestamp":1767456000,"startTime":"0","endTime":"0","summary":"本周新药行业重点分析：2025 年我国创新药行业蓬勃发展，根据NMPA 与药渡数据，2025 年NMPA 共批准了约101 款创新药，这一数量再创近年来获批新药数量的新高；其中2025 年共批准上市国产创新药（含引进）63 款， 进口创新药38 款，国内创新药行业蓬勃发展。本周新药临床申请获批准&受理情况：本周国内有18 个新药的临床申请获批准，有52 个新药的临床申请获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104174118a6f16fa6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104174118a6f16fa6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","HK0000165453.HKD","BK1574","02696","06978"],"gpt_icon":0},{"id":"2600057093","title":"新加坡政府投资公司增持复宏汉霖(02696)17.7万股 每股作价约56.76港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600057093","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600057093?lang=zh_cn&edition=full","pubTime":"2026-01-02 17:44","pubTimestamp":1767347081,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，12月30日，新加坡政府投资公司增持复宏汉霖(02696)17.7万股，每股作价56.7593港元，总金额约为1004.64万港元。增持后最新持股数目为991.71万股，最新持股比例为6.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2600094092","title":"每日卖空追踪 | 复宏汉霖 01月02日卖空量成交1.17万股，卖空比例为3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600094092","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600094092?lang=zh_cn&edition=full","pubTime":"2026-01-02 16:30","pubTimestamp":1767342634,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间01月02日，涨2.72%，卖空量成交1.17万股，较上一交易日增加138.78%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163408a6eb2aec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163408a6eb2aec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2595701817","title":"每日卖空追踪 | 复宏汉霖 12月31日卖空量成交4900股，卖空比例为1.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595701817","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595701817?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:30","pubTimestamp":1767169833,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间12月31日，涨0.09%，卖空量成交4900股，较上一交易日减少40.96%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231163530a48dc87f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231163530a48dc87f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2595770160","title":"复宏汉霖12月31日获主力加仓41.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595770160","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595770160?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:15","pubTimestamp":1767168949,"startTime":"0","endTime":"0","summary":"12月31日, 复宏汉霖股价涨0.09%，报收57.05元，成交金额1665.7万元，换手率0.18%，振幅1.93%，量比0.39。复宏汉霖今日主力资金净流入41.0万元，连续4日净流入，上一交易日主力净流入862.9万元。|12月31日主力加仓幅度排名||#|股票简称|主力净额占比|#|鹏高控股集团|1.68%|#|PACIFICLEGEND|1.11%|#|印象大红袍|0.97%|#|...|...|#332|复宏汉霖|0.00%|（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231162030a48db710&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231162030a48db710&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2595790871","title":"每日卖空追踪 | 复宏汉霖 12月30日卖空量成交3100股，卖空比例为0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595790871","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595790871?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:30","pubTimestamp":1767083432,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间12月30日，跌3.14%，卖空量成交3100股，较上一交易日减少72.32%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230163511a6e07e3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230163511a6e07e3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2594917702","title":"复宏汉霖：DLL3/CD3/CD28三抗申报临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2594917702","media":"医药笔记","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594917702?lang=zh_cn&edition=full","pubTime":"2025-12-26 08:30","pubTimestamp":1766709022,"startTime":"0","endTime":"0","summary":"▎Armstrong2025年12月25日，复宏汉霖HLX3901注射液的临床试验申请获得NMPA受理。HLX3901正是在TAA/CD3/CD28技术平台上构建，该TCE平台在低T细胞浸润下表现出更优的疗效，同时细胞因子释放更低，达到有效性与安全性的更优平衡。总结复宏汉霖在早研方面的深耕，正迎来新一波迭代创新分子的爆发，最近多款创新药申报IND，包括KAT6A/B抑制剂HLX97、DLL3/CD3/CD28三抗HLX3901、B7H3-唾液酸酶融合蛋白HLX316、PD-L1/VEGF双抗HLX37等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251226090102a47958bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251226090102a47958bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2593541395","title":"年内险资举牌39次：偏爱红利资产，科技板块迎布局机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2593541395","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593541395?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:10","pubTimestamp":1766495400,"startTime":"0","endTime":"0","summary":"随着中邮保险的举牌成功，今年险资的举牌次数达到39次，仅次于2015年的62次，为历史第二高。从举牌资产所属板块来看，传统板块仍具有压舱石地位，但科技板块的比重有望增加。截至12月23日，2025年以来险资举牌共计39次，创2016年以来新高。例如，弘康人寿今年6月27日首次举牌郑州银行H股，并在此后进行了16次增持，最新持股比例达22.14%，累计触发4次举牌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122321153997a099a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122321153997a099a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03968","BK1161","02696","01658","01330","HK0000165453.HKD"],"gpt_icon":0},{"id":"2593413948","title":"每日卖空追踪 | 复宏汉霖 12月23日卖空量成交1.34万股，卖空比例为2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413948","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593413948?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:30","pubTimestamp":1766478633,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间12月23日，涨1.08%，卖空量成交1.34万股，较上一交易日减少64.64%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163500a46e18c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163500a46e18c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2593413910","title":"复宏汉霖12月23日主力净流入99.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593413910?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:15","pubTimestamp":1766477734,"startTime":"0","endTime":"0","summary":"12月23日, 复宏汉霖股价涨1.08%，报收61.00元，成交金额2915.5万元，换手率0.30%，振幅7.54%，量比0.80。复宏汉霖今日主力资金净流入99.3万元，上一交易日主力净流出439.6万元。该股近5个交易日上涨2.42%，主力资金累计净流出595.9万元；近20日主力资金累计净流出2179.9万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223161759a6c50a8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223161759a6c50a8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2592152090","title":"复宏汉霖(02696)：纳武利尤单抗生物类似药HLX18用于多种实体瘤治疗的1期临床试验申请获美国食品药品管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592152090","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592152090?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:03","pubTimestamp":1766135031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主研发的纳武利尤单抗生物类似药HLX18用于多种实体瘤治疗的1期临床试验申请获美国食品药品管理局批准。公司拟于条件具备后于美国开展相关1期临床试验。部分肿瘤细胞的PD-1配体上调，通过这个通路信号传导可抑制激活的T细胞对肿瘤的免疫监视。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"复宏汉霖(02696)：纳武利尤单抗生物类似药HLX18用于多种实体瘤治疗的1期临床试验申请获美国食品药品管理局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"1186205755","title":"复宏汉霖 - Nivolumab生物仿制药Hlx18的第一阶段临床试验获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1186205755","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186205755?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:02","pubTimestamp":1766134978,"startTime":"0","endTime":"0","summary":"复宏汉霖 - Nivolumab生物仿制药Hlx18的第一阶段临床试验获得美国FDA批准","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2592189681","title":"每日卖空追踪 | 复宏汉霖 12月19日卖空量成交9100股，卖空比例为1.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592189681","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592189681?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:30","pubTimestamp":1766133032,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间12月19日，涨3.3%，卖空量成交9100股，较上一交易日减少14.15%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163540a45f3710&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163540a45f3710&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2592118640","title":"复宏汉霖12月19日主力净流入12.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2592118640","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592118640?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:15","pubTimestamp":1766132132,"startTime":"0","endTime":"0","summary":"12月19日, 复宏汉霖股价涨3.30%，报收62.55元，成交金额4221.7万元，换手率0.42%，振幅6.85%，量比1.17。复宏汉霖今日主力资金净流入12.2万元，上一交易日主力净流出304.3万元。该股近5个交易日上涨0.69%，主力资金累计净流出343.9万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出1666.8万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219161735a6b62fb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219161735a6b62fb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2592659731","title":"兴业证券：实体瘤TCE技术路径百花齐放 国内企业创新平台布局丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2592659731","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592659731?lang=zh_cn&edition=full","pubTime":"2025-12-19 14:08","pubTimestamp":1766124536,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，兴业证券发布研报称，TCE在血液瘤中的疗效与商业化能力已充分验证，但还需解决几大问题。非全长双抗、2+1格式设计、TCR、前药、共刺激靶点与选择性T细胞靶点等设计进一步增强TCE在实体瘤的适用性。国内公司CD28共刺激多抗、TCEADC、位阻遮蔽设计、TCR疗法等形式的实体瘤TCE研发持续推进，已形成平台化的研发能力与靶点布局丰富的管线梯队。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219144108a45ebf21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219144108a45ebf21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","02696","02142","BK1161"],"gpt_icon":0},{"id":"2592044139","title":"医药股集体走高 药明生物(02269)涨5.93% 机构料明年板块稳中向好态势延续","url":"https://stock-news.laohu8.com/highlight/detail?id=2592044139","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592044139?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:23","pubTimestamp":1766111038,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股集体走高，药明生物 涨5.93%，药明合联涨4.56%，君实生物涨4.54%，康诺亚-B涨4.19%，荣昌生物涨3.98%，科伦博泰生物-B涨4.00%，泰格医药涨4.30%，复宏汉霖涨3.72%，诺诚健华涨3.26%。交银国际发布医药行业周报，展望2026年，该机构认为板块稳中向好态势延续，但影响市场表现的核心因素或呈分化态势，后续选股逻辑或将重回基本面和估值，即关注存在基本面预期差、当前仍被低估的个股。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971870","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","LU0196878994.USD","BK1576","LU0359201612.USD","02269","LU0417516902.SGD","LU0708995583.HKD","LU0327786744.USD","LU0819121731.USD","LU0823426480.USD","LU1242518931.SGD","159938","LU2328871848.SGD","LU2488822045.USD","02162","BK1587","LU0181495838.USD","LU0417516738.SGD","SG9999014674.SGD","01877","IE00B0JY6N72.USD","LU0823426308.USD","09939","HK0000165453.HKD","LU0051755006.USD","LU1688375341.USD","SG9999002562.SGD","LU1969619763.USD","LU0348735423.USD","LU0052750758.USD","02696","03347","06990","BK1161","LU0359202008.SGD","LU1880383366.USD","BK1610","LU0348825331.USD","09969","LU0856984785.SGD","02268","BK1141","09995","BK1521","BK1574","LU0516422366.SGD","LU1242518857.USD","LU0572944931.SGD","LU0588546209.SGD","LU0039217434.USD"],"gpt_icon":0},{"id":"2592529974","title":"复宏汉霖12月18日主力净流出304.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2592529974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592529974?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:15","pubTimestamp":1766045728,"startTime":"0","endTime":"0","summary":"12月18日, 复宏汉霖股价跌0.16%，报收60.55元，成交金额3361.4万元，换手率0.34%，振幅3.63%，量比1.00。复宏汉霖今日主力资金净流出304.3万元，上一交易日主力净流入36.5万元。该股近5个交易日下跌5.95%，主力资金累计净流出483.2万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出1597.5万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218161709a6b19d61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218161709a6b19d61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2591816769","title":"每日卖空追踪 | 复宏汉霖 12月16日卖空量成交1600股，卖空比例为0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591816769","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591816769?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:30","pubTimestamp":1765873831,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间12月16日，跌2.05%，卖空量成交1600股，较上一交易日减少89.4%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216163522a451a014&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216163522a451a014&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2591603079","title":"【券商聚焦】中国银河首予复宏汉霖(02696)“推荐”评级  指其部分产品显示广谱性及BIC潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2591603079","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591603079?lang=zh_cn&edition=full","pubTime":"2025-12-16 14:16","pubTimestamp":1765865816,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国银河研报指出，复宏汉霖 创立于2010年，聚焦血液瘤、实体瘤、自身免疫疾病等领域，是国内最早布局生物类似药的企业。该机构表示，复宏汉霖以全球生物类似药研发和销售为基本盘，布局ADC、单抗等创新管线，部分产品显示广谱性及BIC潜力，后续业绩增长确定性较强，预计公司2025-2027年归母净利润为8.23/7.44/11.29亿元，对应当前股价PE为39/43/28倍，采取绝对估值法计算公司总市值为521-679亿元，首次覆盖，给予“推荐”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971639","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601881","02696"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":-0.1247},{"period":"3month","weight":-0.2027},{"period":"6month","weight":0.0483},{"period":"1year","weight":1.4936},{"period":"ytd","weight":0.0272}],"compareEarnings":[{"period":"1week","weight":0.0201},{"period":"1month","weight":0.0224},{"period":"3month","weight":-0.0296},{"period":"6month","weight":0.1013},{"period":"1year","weight":0.3422},{"period":"ytd","weight":0.0276}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.041138},{"month":2,"riseRate":0.666667,"avgChangeRate":0.108951},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016995},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}